Jorge Camarero

1.2k total citations
21 papers, 865 citations indexed

About

Jorge Camarero is a scholar working on Cellular and Molecular Neuroscience, Oncology and Toxicology. According to data from OpenAlex, Jorge Camarero has authored 21 papers receiving a total of 865 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cellular and Molecular Neuroscience, 8 papers in Oncology and 7 papers in Toxicology. Recurrent topics in Jorge Camarero's work include Neurotransmitter Receptor Influence on Behavior (8 papers), Forensic Toxicology and Drug Analysis (7 papers) and Neuroscience and Neuropharmacology Research (4 papers). Jorge Camarero is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (8 papers), Forensic Toxicology and Drug Analysis (7 papers) and Neuroscience and Neuropharmacology Research (4 papers). Jorge Camarero collaborates with scholars based in Spain, United Kingdom and Netherlands. Jorge Camarero's co-authors include M. Isabel Colado, Esther O’Shea, Verónica Sánchez, B. Moreno Esteban, A. Richard Green, Francesco Pignatti, María Isabel Colado, Marı́a A. Moro, A R Green and J.M. Elliott and has published in prestigious journals such as Journal of Neurochemistry, Annals of Oncology and British Journal of Pharmacology.

In The Last Decade

Jorge Camarero

21 papers receiving 853 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jorge Camarero Spain	14	464	415	275	226	123	21	865
George Grayson United States	11	231 0.5×	129 0.3×	37 0.1×	361 1.6×	239 1.9×	12	793
Isabel Hervías Spain	15	244 0.5×	78 0.2×	39 0.1×	153 0.7×	411 3.3×	19	864
Hongfeng Deng United States	11	498 1.1×	144 0.3×	57 0.2×	798 3.5×	254 2.1×	15	1.1k
Hengjun He United States	7	190 0.4×	73 0.2×	36 0.1×	204 0.9×	209 1.7×	8	456
Andreas Goutopoulos United States	16	575 1.2×	172 0.4×	15 0.1×	911 4.0×	253 2.1×	27	1.2k
Ananthakrishnan Sankaranarayanan United States	8	335 0.7×	57 0.1×	37 0.1×	25 0.1×	613 5.0×	11	914
Hans G. Cruz United States	15	512 1.1×	37 0.1×	18 0.1×	39 0.2×	524 4.3×	29	1.0k
Maneesh Gupta United States	17	205 0.4×	83 0.2×	15 0.1×	18 0.1×	385 3.1×	34	903
Concepción Villanueva Spain	8	280 0.6×	45 0.1×	27 0.1×	760 3.4×	318 2.6×	10	1.1k
Helen Hendrickson United States	13	134 0.3×	49 0.1×	15 0.1×	48 0.2×	214 1.7×	14	832

Countries citing papers authored by Jorge Camarero

Since Specialization

Citations

This map shows the geographic impact of Jorge Camarero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge Camarero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge Camarero more than expected).

Fields of papers citing papers by Jorge Camarero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorge Camarero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge Camarero. The network helps show where Jorge Camarero may publish in the future.

Co-authorship network of co-authors of Jorge Camarero

This figure shows the co-authorship network connecting the top 25 collaborators of Jorge Camarero. A scholar is included among the top collaborators of Jorge Camarero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge Camarero. Jorge Camarero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Delgado, Julio, Filip Josephson, Jorge Camarero, et al.. (2021). EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. The Oncologist. 26(3). 242–249. 8 indexed citations

Camarero, Jorge, Paula B. van Hennik, B. Bolstad, et al.. (2020). European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma. ESMO Open. 5(6). e000798–e000798. 5 indexed citations

Moscetti, Luca, Paula B. van Hennik, B. Bolstad, et al.. (2020). Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects. ESMO Open. 5(4). e000856–e000856. 1 indexed citations

Camarero, Jorge. (2019). ES10.04 European Medicines Agency. Journal of Thoracic Oncology. 14(10). S38–S39. 1 indexed citations

Moreau, Alexandre, Daniela Melchiorri, Jorge Camarero, et al.. (2019). Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease. The Oncologist. 25(4). e709–e715. 13 indexed citations

Bowen, Debra L., Jorge Camarero, Pierre Démolis, et al.. (2015). Early market access of cancer drugs in the EU. Annals of Oncology. 27(1). 96–105. 61 indexed citations

Enzmann, Harald, Jorge Camarero, Tomas Salmonson, et al.. (2014). The European Medicines Agency Review of Bosutinib for the Treatment of Adult Patients With Chronic Myelogenous Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. The Oncologist. 19(4). 421–425. 6 indexed citations

Camarero, Jorge, et al.. (2012). Cancer immunotherapy products. Human Vaccines & Immunotherapeutics. 8(9). 1354–1359. 1 indexed citations

Zwieten‐Boot, Barbara van, Gonzalo Calvo, Maaike van Dartel, et al.. (2011). The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. European Journal of Cancer. 48(2). 237–242. 46 indexed citations

10.

Zwieten‐Boot, Barbara van, et al.. (2011). The European Medicines Agency Review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the Treatment of Advanced Gastric Cancer When Given in Combination with Cisplatin: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use (CHMP). The Oncologist. 16(10). 1451–1457. 31 indexed citations

11.

O’Shea, Esther, Laura Orío, Isabel Escobedo, et al.. (2006). MDMA‐induced neurotoxicity: long‐term effects on 5‐HT biosynthesis and the influence of ambient temperature. British Journal of Pharmacology. 148(6). 778–785. 42 indexed citations

12.

Orío, Laura, Esther O’Shea, Verónica Sánchez, et al.. (2004). 3,4‐Methylenedioxymethamphetamine increases interleukin‐1β levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5‐HT depletion. Journal of Neurochemistry. 89(6). 1445–1453. 62 indexed citations

13.

Sánchez, Verónica, Miriam Zeini, Jorge Camarero, et al.. (2003). The nNOS inhibitor, AR‐R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum. Journal of Neurochemistry. 85(2). 515–524. 33 indexed citations

14.

O’Shea, Esther, Verónica Sánchez, Jorge Camarero, A. Richard Green, & María Isabel Colado. (2002). On the protection against methamphetamine-induced neurotoxicity by benzamide, a PARP inhibitor. Psychopharmacology. 165(3). 317–319. 6 indexed citations

15.

Camarero, Jorge, Verónica Sánchez, Esther O’Shea, A. Richard Green, & María Isabel Colado. (2002). Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4‐methylenedioxymethamphetamine (‘ecstasy’)‐induced dopamine release and free radical formation in the mouse striatum. Journal of Neurochemistry. 81(5). 961–972. 61 indexed citations

16.

Sánchez, Violeta Sánchez, et al.. (2001). The mechanisms involved in the long‐lasting neuroprotective effect of fluoxetine against MDMA (‘ecstasy’)‐induced degeneration of 5‐HT nerve endings in rat brain. British Journal of Pharmacology. 134(1). 46–57. 83 indexed citations

17.

Colado, M. Isabel, Jorge Camarero, Annis O. Mechan, et al.. (2001). A study of the mechanisms involved in the neurotoxic action of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on dopamine neurones in mouse brain. British Journal of Pharmacology. 134(8). 1711–1723. 98 indexed citations

18.

O’Shea, Esther, et al.. (2001). Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA (‘ecstasy’) on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology. 40(1). 65–74. 83 indexed citations

19.

Esteban, B. Moreno, Esther O’Shea, Jorge Camarero, et al.. (2001). 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology. 154(3). 251–260. 127 indexed citations

20.

Cristóbal, Javier de, Marı́a A. Moro, Antoni Dávalos, et al.. (2001). Neuroprotective effect of aspirin by inhibition of glutamate release after permanent focal cerebral ischaemia in rats. Journal of Neurochemistry. 79(2). 456–459. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact